Biotech Firms Participate in Upcoming Conferences; Sees Steady Numbers around Thanksgiving - Research Report on BioMarin, Halozyme, PDL BioPharma, Anika Therapeutics, and Exelis
NEW YORK, December 3, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Halozyme Therapeutics, Inc. (NASDAQ: HALO), PDL BioPharma Inc. (NASDAQ: PDLI),
Anika Therapeutics, Inc. (NASDAQ: ANIK), and Exelixis, Inc. (NASDAQ: EXEL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
BioMarin Pharmaceutical Inc. Research Report
On November 27, 2013, BioMarin Pharmaceutical Inc.'s (BioMarin) stock rose 0.28% to $70.73 at the end of trading. Over the previous three trading sessions, BioMarin's shares dipped 0.44% when compared to the Nasdaq composite, which gained 1.33% during the same period. In another release dated November 26, 2013, the Company announced that its Executive Vice President and CFO Dan Spiegelman will present at the Deutsche Bank 2013 BioFest Conference on Tuesday, December 3, 2013 at 9:35 a.m. ET. The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/9b6c_BMRN
Halozyme Therapeutics, Inc. Research Report
On November 26, 2013, Halozyme Therapeutics, Inc. (Halozyme) announced its participation at the upcoming Piper Jaffray Healthcare Conference on Tuesday, December 3, 2013. Halozyme's President and CEO Gregory I. Frost will provide a corporate overview at 12:00 p.m. ET/9:00 a.m. PT. The presentation will be webcast through the Investors section of the Company's website. The Full Research Report on Halozyme Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/ea1b_HALO
PDL BioPharma Inc. Research Report
On November 27, 2013, shares of PDL BioPharma Inc. (PDL BioPharma) rose 1.15% to end trading at $9.66 per share. Over the previous three trading sessions, PDL BioPharma's shares gained 2.99% while the Nasdaq composite also gained 1.33% during the same period. The Full Research Report on PDL BioPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/066b_PDLI
Anika Therapeutics, Inc. Research Report
On November 27, 2013, Anika Therapeutics, Inc.'s (Anika Therapeutics) shares stood at $34.30 at the close, indicating a 1.27% increase. Anika Therapeutics' shares rose 12.87% over the previous three trading sessions while the Nasdaq composite gained 1.33% during the same period. The Full Research Report on Anika Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/ae5d_ANIK
Exelixis, Inc. Research Report
On November 26, 2013, Exelixis, Inc. (Exelis) announced that its President and CEO, Michael M. Morrissey, Ph.D., will present at the 25th Annual Piper Jaffray Healthcare Conference at 10:30 a.m. EST/7:30 a.m. PST on Tuesday, December 3, 2013 in New York. Dr. Morrissey will review the Company's development plans and priorities for cabozantinib. Dr. Morrissey will also discuss the Company's corporate strategy and financial outlook, and provide a general business update. The Full Research Report on Exelixis, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/73be_EXEL
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article